CN104780921A - Hcv的大环蛋白酶抑制剂、非核苷hcv抑制剂和利托那韦的组合 - Google Patents

Hcv的大环蛋白酶抑制剂、非核苷hcv抑制剂和利托那韦的组合 Download PDF

Info

Publication number
CN104780921A
CN104780921A CN201380045145.7A CN201380045145A CN104780921A CN 104780921 A CN104780921 A CN 104780921A CN 201380045145 A CN201380045145 A CN 201380045145A CN 104780921 A CN104780921 A CN 104780921A
Authority
CN
China
Prior art keywords
compound
formula
hcv
combination
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380045145.7A
Other languages
English (en)
Chinese (zh)
Inventor
M-C.劳安
J.斯诺伊斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Janssen Pharmaceuticals Inc filed Critical Ortho McNeil Janssen Pharmaceuticals Inc
Publication of CN104780921A publication Critical patent/CN104780921A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380045145.7A 2012-08-31 2013-08-30 Hcv的大环蛋白酶抑制剂、非核苷hcv抑制剂和利托那韦的组合 Pending CN104780921A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12182551 2012-08-31
EP12182551.7 2012-08-31
EP12185890.6 2012-09-25
EP12185890 2012-09-25
PCT/IB2013/058138 WO2014033668A2 (en) 2012-08-31 2013-08-30 Combination of a macrocyclic protease inhibitor of hcv, a non-nucleoside hcv inhibitor and ritonavir

Publications (1)

Publication Number Publication Date
CN104780921A true CN104780921A (zh) 2015-07-15

Family

ID=49920362

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380045145.7A Pending CN104780921A (zh) 2012-08-31 2013-08-30 Hcv的大环蛋白酶抑制剂、非核苷hcv抑制剂和利托那韦的组合

Country Status (12)

Country Link
US (1) US20150209366A1 (enExample)
EP (1) EP2890378A2 (enExample)
JP (1) JP2015526504A (enExample)
KR (1) KR20150046083A (enExample)
CN (1) CN104780921A (enExample)
AU (1) AU2013311025A1 (enExample)
BR (1) BR112015003913A2 (enExample)
CA (1) CA2881052A1 (enExample)
IL (1) IL237049A0 (enExample)
MX (1) MX2015002684A (enExample)
RU (1) RU2015111491A (enExample)
WO (1) WO2014033668A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106727516A (zh) * 2017-01-10 2017-05-31 山东省立医院 一种治疗丙型肝炎的药物组合物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI454476B (zh) 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
WO2020001814A1 (en) 2018-06-27 2020-01-02 Robert Bosch Gmbh Method for operating a hybrid powertrain with an electric machine, an internal combustion engine and a variable transmission

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997001349A1 (en) * 1995-06-29 1997-01-16 Abbott Laboratories Use of ritonavir (abt-538) for improving the pharmacokinetics of drugs metabolized by cytochrome p450 in a method of treating aids
CN101228169A (zh) * 2005-07-29 2008-07-23 泰博特克药品有限公司 丙型肝炎病毒的大环抑制剂
WO2011128378A1 (en) * 2010-04-13 2011-10-20 Janssen Pharmaceuticals, Inc. Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside
CN102356080A (zh) * 2009-02-27 2012-02-15 奥索-麦克尼尔-詹森药品公司 Hcv大环抑制剂的无定形盐

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI454476B (zh) 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997001349A1 (en) * 1995-06-29 1997-01-16 Abbott Laboratories Use of ritonavir (abt-538) for improving the pharmacokinetics of drugs metabolized by cytochrome p450 in a method of treating aids
CN101228169A (zh) * 2005-07-29 2008-07-23 泰博特克药品有限公司 丙型肝炎病毒的大环抑制剂
CN102356080A (zh) * 2009-02-27 2012-02-15 奥索-麦克尼尔-詹森药品公司 Hcv大环抑制剂的无定形盐
WO2011128378A1 (en) * 2010-04-13 2011-10-20 Janssen Pharmaceuticals, Inc. Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106727516A (zh) * 2017-01-10 2017-05-31 山东省立医院 一种治疗丙型肝炎的药物组合物

Also Published As

Publication number Publication date
JP2015526504A (ja) 2015-09-10
WO2014033668A3 (en) 2014-05-01
MX2015002684A (es) 2015-05-12
EP2890378A2 (en) 2015-07-08
CA2881052A1 (en) 2014-03-06
AU2013311025A1 (en) 2015-02-26
KR20150046083A (ko) 2015-04-29
US20150209366A1 (en) 2015-07-30
BR112015003913A2 (pt) 2017-07-04
IL237049A0 (en) 2015-03-31
RU2015111491A (ru) 2016-10-20
WO2014033668A2 (en) 2014-03-06

Similar Documents

Publication Publication Date Title
JP2012502956A (ja) Ｈｃｖの大環状阻害剤とヌクレオシドの相乗性組み合わせ剤
WO2010031832A9 (en) Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative
JP2008530124A (ja) フラビウイルス感染症を処置または予防するための組成物および方法
CN101743004A (zh) 治疗用组合物及其用途
CN108135979A (zh) Hbv衣壳组装抑制剂和干扰素的组合疗法
CA2999516A1 (en) Compounds and combinations for the treatment of hiv
JP2021515769A (ja) カプシド集合調節剤の投薬レジメン
JP2006511538A (ja) 非ヌクレオシド系逆転写酵素阻害剤（ｎｎｒｔｉ）とプロテアーゼ阻害剤などのシトクロムｐ４５０の阻害剤とを含む組み合わせの使用
WO2017156391A1 (en) Compounds and compositions for the treatment of infections
CN104780921A (zh) Hcv的大环蛋白酶抑制剂、非核苷hcv抑制剂和利托那韦的组合
CA2863645A1 (en) Once daily treatment of hepatitis c with ribavirin and taribavirin
CN102844028B (zh) Hcv大环抑制剂、非核苷和核苷的组合
JP2017514834A (ja) Ｈｃｖ感染症を治療するための組合せ療法
HK1180222B (en) Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside
HK1161833A (en) Synergistic combinations of a macrocyclic inhibitor of hcv and nucleoside

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150715

WD01 Invention patent application deemed withdrawn after publication